贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300558 贝达药业

已收盘 01-06 15:00:00

{"stockData":{"symbol":"300558","market":"SZ","secType":"STK","nameCN":"贝达药业","latestPrice":49.35,"timestamp":1767683025000,"preClose":48.9,"halted":0,"volume":6762532,"delay":0,"changeRate":0.0092,"floatShares":419000000,"shares":421000000,"eps":0.7209,"marketStatus":"已收盘","change":0.45,"latestTime":"01-06 15:00:00","open":48.91,"high":49.49,"low":48.57,"amount":332000000,"amplitude":0.0188,"askPrice":49.36,"askSize":26,"bidPrice":49.35,"bidSize":171,"shortable":0,"etf":0,"ttmEps":0.7209,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767749400000},"marketStatusCode":5,"adr":0,"adjPreClose":48.9,"symbolType":"stock","openAndCloseTimeList":[[1767663000000,1767670200000],[1767675600000,1767682800000]],"highLimit":53.79,"lowLimit":44.01,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":420733843,"isCdr":false,"pbRate":3.52,"roa":"--","peRate":68.456097,"roe":"5.5%","epsLYR":0.96,"committee":0.473684,"marketValue":20763000000,"turnoverRate":0.0161,"status":0,"floatMarketCap":20697000000},"requestUrl":"/m/hq/s/300558","defaultTab":"news","newsList":[{"id":"2601109188","title":"股市必读：贝达药业（300558）1月6日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2601109188","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601109188?lang=zh_cn&edition=full","pubTime":"2026-01-07 03:51","pubTimestamp":1767729068,"startTime":"0","endTime":"0","summary":"截至2026年1月6日收盘，贝达药业报收于49.35元，上涨0.92%，换手率1.61%，成交量6.76万手，成交额3.32亿元。杭州景曜生物科技有限责任公司自2025年10月成立后尚未进行实际业务的开展，公司受让股权除了承担该公司的注册资本出资责任外，未支付其他费用。公司已按工作业务的相关进展预约2026年4月23日为2025年年度报告披露日。目前公司经营正常，2025年经营业绩相关信息请以公司公开披露为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700001698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"gpt_icon":0},{"id":"2601861579","title":"贝达药业：BPI-572270项目临床申请正在审核中","url":"https://stock-news.laohu8.com/highlight/detail?id=2601861579","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601861579?lang=zh_cn&edition=full","pubTime":"2026-01-06 15:12","pubTimestamp":1767683538,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业01月06日在投资者关系平台上答复投资者关心的问题。投资者提问：在2025.12.31承认景曜是子公司了？请做具体解释？！公司一贯遵循法律法规及交易所规则，对于应当披露事项的进展情况及时履行披露义务。根据实际业务开展的需要，公司推进BPI-572270项目的临床申报工作，完成的工作节点均不属于公司法定披露的时点。目前，项目的临床申请正在审核当中，如有重大进展，公司会及时公告披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600019897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"gpt_icon":0},{"id":"2601100060","title":"贝达药业（300558）披露2026年度日常关联交易预计，1月5日股价上涨4.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601100060","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601100060?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:21","pubTimestamp":1767608514,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，贝达药业报收于48.9元，较前一交易日上涨4.73%，最新总市值为205.74亿元。该股当日开盘46.73元，最高49.38元，最低46.62元，成交额达4.39亿元，换手率为2.16%。近日，贝达药业发布2025年第二次临时股东大会决议公告，公司于2025年12月31日召开2025年第二次临时股东大会，审议通过了关于2026年度日常关联交易预计的议案。本次股东大会采用现场投票与网络投票相结合的方式进行，表决结果均获通过，律师见证本次股东大会合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500028631.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300558"],"gpt_icon":0},{"id":"2600023773","title":"21健讯Daily | 国药控股与贝达药业达成战略合作；遵义市第一人民医院副院长被查","url":"https://stock-news.laohu8.com/highlight/detail?id=2600023773","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600023773?lang=zh_cn&edition=full","pubTime":"2026-01-04 22:14","pubTimestamp":1767536079,"startTime":"0","endTime":"0","summary":"这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！政策动向国务院常务会议审议通过《中华人民共和国药品管理法实施条例（修订草案）》2025年12月31日召开的国务院常务会议，审议通过《中华人民共和国药品管理法实施条例(修订草案)》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601043608001973.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601043608001973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0640798160.USD","BK0060","LU1115378108.SGD","BK0239","300558","BK1197","BK1500","01099","BK1515"],"gpt_icon":0},{"id":"2600045058","title":"深化战略协同 共拓发展新篇——国药控股与贝达药业达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2600045058","media":"国药控股股份有...","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600045058?lang=zh_cn&edition=full","pubTime":"2026-01-04 12:39","pubTimestamp":1767501540,"startTime":"0","endTime":"0","summary":"近日，“国药控股&贝达药业战略合作签约仪式暨项目启动会”在贝达总部举行。国药控股副总裁胡立刚、国控多家子公司领导，贝达药业董事长丁列明博士，贝达药业副总裁范建勋、马勇斌、刘 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260104/c673715319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","300558","BK0060"],"gpt_icon":0},{"id":"2595776067","title":"贝达药业：持有翰思艾泰5.45%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2595776067","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595776067?lang=zh_cn&edition=full","pubTime":"2025-12-31 19:54","pubTimestamp":1767182047,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)12月31日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司对翰思艾泰-B的持有比例为多少？贝达药业回复：您好！公司持有翰思艾泰生物医药科技（武汉）股份有限公司5.45%的股份。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100040077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1173","BK1535","300558","BK0239","BK0060"],"gpt_icon":0},{"id":"2595776066","title":"贝达药业：帕妥珠单抗上市申报稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2595776066","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595776066?lang=zh_cn&edition=full","pubTime":"2025-12-31 19:54","pubTimestamp":1767182047,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)12月31日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，公司的帕妥珠单抗有没有同步推进皮下制剂研发，以弥补剂型短板，提升市场长期竞争力？贝达药业回复：您好！帕妥珠单抗的上市申报审核工作正在稳步推进中，公司会关注产品的新剂型的特点，结合公司开发计划和市场需求综合评估、安排。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100040076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300558","BK0060"],"gpt_icon":0},{"id":"2595776106","title":"贝达药业：梦工场二期平台效能逐步实现","url":"https://stock-news.laohu8.com/highlight/detail?id=2595776106","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595776106?lang=zh_cn&edition=full","pubTime":"2025-12-31 19:45","pubTimestamp":1767181517,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)12月31日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贝达梦工厂2025年度的招商入住情况如何？贝达药业回复：您好！贝达梦工场二期建成后已按照公司实际情况和需求逐步实现平台效能，包括结合公司的发展经验和开发资源引进、助力初创型生物医药企业的发展，目前相关的工作正在有序推进中。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100039774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300558"],"gpt_icon":0},{"id":"2595764627","title":"贝达药业：港股IPO基于整体战略发展考量","url":"https://stock-news.laohu8.com/highlight/detail?id=2595764627","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595764627?lang=zh_cn&edition=full","pubTime":"2025-12-31 19:45","pubTimestamp":1767181509,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业12月31日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司市值不足200亿，如此低迷行情下，港股IPO的发行会不会损害原有股东利益？自从发布港股IPO，贵公司股价持续走弱，跌幅达40%以上，在此期间贵公司是否有市值维护等举措？公司始终重视股东利益，港股IPO是基于整体战略发展的考量，旨在拓宽融资渠道、优化资本结构、提升国际影响力，目前相关的上市工作正在有序推进中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100039769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300558"],"gpt_icon":0},{"id":"2595977637","title":"贝达药业：通过“四驾马车”协同发力力争实现公司更大突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2595977637","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595977637?lang=zh_cn&edition=full","pubTime":"2025-12-31 19:36","pubTimestamp":1767180971,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业12月31日在投资者关系平台上答复投资者关心的问题。贝达对标高质量发展提出了未来五年的发展规划，通过“四驾马车”协同发力，在核心创新力、人才资源、制度保障以及执行力方面均制定了相应的目标和具体的措施，力争实现公司的更大突破，全力创造公司价值，推动公司实现跨越式发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100039425.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0060","BK0239"],"gpt_icon":0},{"id":"2595763357","title":"贝达药业：恩沙替尼补充申请为说明书修订","url":"https://stock-news.laohu8.com/highlight/detail?id=2595763357","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595763357?lang=zh_cn&edition=full","pubTime":"2025-12-31 19:33","pubTimestamp":1767180786,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)12月31日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司 2025-11-18关于恩莎替尼的补充申请的具体内容是什么？为何没有进行相关披露？贝达药业回复：您好！本次恩沙替尼补充申请为药品说明书修订事项，属于常规申报类型，该环节不涉及法定信息披露义务。后续如有相关临床或注册重要进展，公司将按法规规定及时公告披露。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100039330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0060","BK0239"],"gpt_icon":0},{"id":"2595768117","title":"贝达药业：抗体-溶瘤病毒组合疗法正按计划推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2595768117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595768117?lang=zh_cn&edition=full","pubTime":"2025-12-31 19:27","pubTimestamp":1767180427,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)12月31日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司与康万达合作开发的VM - 001项目，目前进展如何？贝达药业回复：您好！公司与康万达共同开发的抗体-溶瘤病毒组合疗法（V113+BK-001）正在按计划推进中，如有重大节点公司会及时公告披露。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100039121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"gpt_icon":0},{"id":"2595750107","title":"贝达药业：对杭州贝橙创业投资合伙企业出资","url":"https://stock-news.laohu8.com/highlight/detail?id=2595750107","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595750107?lang=zh_cn&edition=full","pubTime":"2025-12-31 19:27","pubTimestamp":1767180427,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)12月31日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司三季度报显示长期股权投资增长较多，主要是对哪些公司的投资？贝达药业回复：您好！截至2025年9月30日，长期股权投资增长主要系公司按照合同条款规定对杭州贝橙创业投资合伙企业（有限合伙）出资。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100039122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300558","BK0239"],"gpt_icon":0},{"id":"2595577681","title":"贝达药业：BPI-572270项目由子公司申报","url":"https://stock-news.laohu8.com/highlight/detail?id=2595577681","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595577681?lang=zh_cn&edition=full","pubTime":"2025-12-31 19:24","pubTimestamp":1767180254,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)12月31日在投资者关系平台上答复投资者关心的问题。投资者提问：Cde管网，景曜生物申报了BPI572270临床，是不是说明这个项目早就是景曜生物的产权了。虽然没有任何公告表明贝达药业与景曜生物有过这方面的交易，而且贝达药业的港股招股书仍然是列为贝达的项目，会不会构成欺诈投资者，影响H股发行？贝达药业回复：您好！BPI-572270项目已由公司全资子公司杭州景曜生物科技有限责任公司提交申报。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100038959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0060","BK0239"],"gpt_icon":0},{"id":"2595720494","title":"贝达药业（300558）披露关于股东股份质押变动的公告，12月31日股价上涨0.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595720494","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595720494?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:43","pubTimestamp":1767174187,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，贝达药业报收于46.69元，较前一交易日上涨0.06%，最新总市值为196.44亿元。公司近日发布公告称，股东宁波凯铭投资管理合伙企业部分股份解除质押，合计解除质押9,300,000股，占其所持股份比例11.62%，占公司总股本比例2.21%。凯铭投资具备相应资金偿付能力，股份质押无平仓风险，不影响公司控制权稳定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100032514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0060","BK0239"],"gpt_icon":0},{"id":"2593461476","title":"贝达药业股东凯铭投资新增质押934.94万股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2593461476","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593461476?lang=zh_cn&edition=full","pubTime":"2025-12-24 18:25","pubTimestamp":1766571927,"startTime":"0","endTime":"0","summary":"中访网数据 贝达药业股份有限公司于今日发布公告，披露其控股股东一致行动人宁波凯铭投资管理合伙企业所持公司部分股份发生质押变动。根据公告，凯铭投资于2025年12月22日新增质押其持有的公司股份9,349,400股，占其所持股份比例的11.68%，占公司总股本的2.22%。　　本次质押变动后，凯铭投资累计质押股份数量增至61,130,804股，占其持股总数的76.35%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251224/31889218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","91287","BK0060","300558"],"gpt_icon":0},{"id":"2591678489","title":"贝达药业拟使用不超过2亿元闲置募集资金补充流动资金","url":"https://stock-news.laohu8.com/highlight/detail?id=2591678489","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591678489?lang=zh_cn&edition=full","pubTime":"2025-12-16 08:04","pubTimestamp":1765843499,"startTime":"0","endTime":"0","summary":"根据议案，公司计划在不影响募集资金投资项目正常进行的前提下，使用额度不超过人民币2亿元的闲置募集资金暂时补充流动资金，使用期限自董事会审议通过之日起不超过12个月。此前，公司于2024年12月使用的1.8亿元闲置募集资金已于2025年11月28日全额归还至募集资金专户。本次使用闲置募集资金暂时补充流动资金事项已履行必要的内部决策程序。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251216/31867290.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300558","BK0060","91287","BK0239"],"gpt_icon":0},{"id":"2591678430","title":"贝达药业独立董事候选人JIANWEI XUAN承诺将取得任职资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2591678430","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591678430?lang=zh_cn&edition=full","pubTime":"2025-12-16 08:04","pubTimestamp":1765843489,"startTime":"0","endTime":"0","summary":"根据公司同日披露的公告，截至本次董事会决议公告发出之日，JIANWEI XUAN尚未取得深圳证券交易所认可的独立董事资格证书。为此，JIANWEI XUAN已出具书面承诺，表示将积极报名参加深交所组织的最近一期独立董事培训，并承诺取得相关资格证书，以满足《上市公司独立董事管理办法》及深交所相关规则对独立董事的任职要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251216/31867277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","300558","BK0060","91287"],"gpt_icon":0},{"id":"2589689879","title":"贝达药业最新公告：公司四款产品纳入《国家医保药品目录》","url":"https://stock-news.laohu8.com/highlight/detail?id=2589689879","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589689879?lang=zh_cn&edition=full","pubTime":"2025-12-07 16:20","pubTimestamp":1765095612,"startTime":"0","endTime":"0","summary":"贝达药业(300558.SZ)公告称，公司产品盐酸埃克替尼片（凯美纳）、盐酸恩沙替尼胶囊（贝美纳）、甲磺酸贝福替尼胶囊（赛美纳）以及伏罗尼布片（伏美纳）被纳入《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》。此次纳入将提高产品的可及性，对销售产生积极影响。但对公司当期经营业绩的影响目前无法准确估计。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120700003973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0060","91287","BK0239"],"gpt_icon":0},{"id":"2588908882","title":"贝达药业(300558.SZ)：目前未有贝福替尼和泰瑞西利的全球多中心临床计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2588908882","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588908882?lang=zh_cn&edition=full","pubTime":"2025-12-02 10:07","pubTimestamp":1764641223,"startTime":"0","endTime":"0","summary":"格隆汇12月2日丨贝达药业(300558.SZ)在投资者互动平台表示，公司目前未有贝福替尼和泰瑞西利的全球多中心临床计划，如有重大合作或交易公司会及时公开披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251202/31837584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","91287","300558","BK0060"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767734746222,"stockEarnings":[{"period":"1week","weight":0.0577},{"period":"1month","weight":0.0352},{"period":"3month","weight":-0.2613},{"period":"6month","weight":-0.1425},{"period":"1year","weight":-0.0671},{"period":"ytd","weight":0.057}],"compareEarnings":[{"period":"1week","weight":0.0299},{"period":"1month","weight":0.0463},{"period":"3month","weight":0.0517},{"period":"6month","weight":0.1635},{"period":"1year","weight":0.2734},{"period":"ytd","weight":0.0289}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"贝达药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"34761人(较上一季度增加17.69%)","perCapita":"12065股","listingDate":"2016-11-07","address":"浙江省杭州市临平区经济技术开发区兴中路355号","registeredCapital":"42073万元","survey":"　　贝达药业股份有限公司的主营业务是创新药物的生产与销售。公司的主要产品是凯美纳、贝美纳、贝安汀、赛美纳、伏美纳、康美纳、安瑞泽、奥福民。","listedPrice":17.57},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"贝达药业,300558,贝达药业股票,贝达药业股票老虎,贝达药业股票老虎国际,贝达药业行情,贝达药业股票行情,贝达药业股价,贝达药业股市,贝达药业股票价格,贝达药业股票交易,贝达药业股票购买,贝达药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}